Cargando…
The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease
OBJECTIVE: Sodium glucose co-transporter 2 inhibitor (SGLT-2i), recommended for patients with type 2 diabetes, has been reported to improve the liver function test results in non-alcoholic fatty liver disease (NAFLD). However, the long-term effects of SGLT-2i on the liver function and body weight in...
Autores principales: | Yamashima, Mio, Miyaaki, Hisamitsu, Miuma, Satoshi, Shibata, Hidetaka, Sasaki, Ryu, Haraguchi, Masafumi, Fukushima, Masanori, Nakao, Kazuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702010/ https://www.ncbi.nlm.nih.gov/pubmed/31308341 http://dx.doi.org/10.2169/internalmedicine.2566-18 |
Ejemplares similares
-
Hypoglycemia measured by flash glucose monitoring system predicts liver-related events in chronic liver disease patients
por: Sasaki, Ryu, et al.
Publicado: (2023) -
Shunt occlusion prior to lenvatinib administration prevents hepatic encephalopathy and hyperammonemia
por: Kuwahara, Ai, et al.
Publicado: (2020) -
The impact of single-nucleotide polymorphisms on liver stiffness and controlled attenuation parameter in patients treated with direct-acting antiviral drugs for hepatitis C infection
por: Matsumoto, Kosuke, et al.
Publicado: (2022) -
Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022) -
Influence of Interferon-free Direct-acting Antiviral Therapy on Primary Hepatocellular Carcinoma Recurrence: A Landmark Time Analysis and Time-dependent Extended Cox Proportional Hazards Model Analysis
por: Miuma, Satoshi, et al.
Publicado: (2020)